The Effect and Mechanism of Action of Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-3 in Human Breast Cancer; A Systematic Review

Document Type : Review Article

Authors

1 MSC Student, Department of Medical Biochemistry, School of Pharmacy and Pharmaceutical Sciences AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

2 PhD Student, Department of Medical Biochemistry, School of Pharmacy and Pharmaceutical Sciences AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

3 Assistant Professor, Department of Medical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Breast cancer is the most common malignancy in women. Many factors such as estrogens, nutrition, etc. play role in the incidence of this cancer. Insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) are the factors recently considered as  components of insulin-like growth factor (IGF) system.Methods: Studies in this field from 1987 to 2012 by using the databases of NCBI (http://www.ncbi.nlm.nih.gov/) were analyzed and reviewedFindings: 1181 article had examined the effect of IGF-1 in breast cancer. 46 showed a direct association with breast cancer. 92 articles were studied relation of IGF-1 and IGFBP-3 with breast cancer, 9 of them were review articles. Of these, 30 articles were selected as the main references.Conclusion: Studies have shown that IGF-1 gene expression increases in breast cancer. IGF-1 effects in growth, proliferation and tumor genesis is mediated by IGF-1R. IGFBP3 inhibit IGF-1 effects by preventing its binding to a surface receptor (IGF-1R) and interferes with IGF-1 mitoses action. Also, in a mechanism independent on IGF, IGFBP-3 binds to specific membrane proteins and induces apoptosis and inhibits cell growth.

Keywords

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62(1): 10-29.
  2. Panjehpour M, Taher MA, Bayesteh M. The growth inhibitory effects of cadmium and copper on the MDA-MB468 human breast cancer cells. J Res Med Sci 2010; 15(5): 279-86.
  3. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92(18): 1472-89.
  4. Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 2010; 28(33): 4985-95.
  5. Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JM, Ashworth A, et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14(1): 2-19.
  6. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363(9418): 1346-53.
  7. Gennigens C, Menetrier-Caux C, Droz JP. Insulin-Like Growth Factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006; 58(2): 124-45.
  8. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195(2): 127-37.
  9. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16(1): 3-34.
  10. Orciari S, Di NS, Lazzarini R, Caprari P, Procopio A, Catalano A. The effects of insulin and insulin-like growth factors on tumor vascularization: new insights of insulin-like growth factor family in cancer. Curr Med Chem 2009; 16(30): 3931-42.
  11. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012; 104(13): 975-81.
  12. Gallagher EJ, LeRoith D. Minireview: IGF, Insulin, and Cancer. Endocrinology. 2011; 152(7): 2546-51.
  13. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2006; 13(2): 593-605.
  14. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009; 101(1): 48-60.
  15. Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 2010; 11(6): 530-42.
  16. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999; 18(15): 2471-9.
  17. Davison Z, de Blacquiere GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 2011; 13(6): 504-15.
  18. Zhu C, Qi X, Chen Y, Sun B, Dai Y, Gu Y. PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol 2011; 137(11): 1587-94.
  19. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, et al. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 2000; 275(43): 33607-13.
  20. Dar AA, Majid S, Nosrati M, de SD, Federman S, Kashani-Sabet M. Functional modulation of IGF-binding protein-3 expression in melanoma. J Invest Dermatol 2010; 130(8): 2071-9.
  21. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 1999; 140(3): 1319-28.
  22. Ibrahim YH, Yee D. Insulin-like growth factor-I and breast cancer therapy. Clin Cancer Res 2005; 11(2 Pt 2): 944s-50s.
  23. Abbasi Kajani A, Mofid MR, Abolfazli K, Tafreshi SA. Encapsulated activated charcoal as a potent agent for improving taxane synthesis and recovery from cultures. Biotechnol Appl Biochem 2010; 56(2): 71-6.
  24. Abbasi Kejani A, Hosseini Tafreshi SA, Khayyam Nekouei SM, Mofid MR. Efficient isolation of high quality nucleic acids from different tissues of Taxus baccata L. Mol Biol Rep 2010; 37(2): 797-800.
  25. Giles ED, Singh G. Role of insulin-like growth factor binding proteins (IGFBPs) in breast cancer proliferation and metastasis. Clin Exp Metastasis 2003; 20(6): 481-7.
  26. Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP. Insulin-like growth factor-binding protein-3 and breast cancer survival. Int J Cancer 1998; 79(6): 624-8.
  27. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28(1): 20-47.
  28. Farahmand L, Majidzadeh A, Sepehrizadeh Z, Mofid MR, Esmaeili R, Yazdi MT. Ligation Independent Cloning of Polycistronic, Genetically Modified, HuMAb4D5-8 F (ab') 2, in Bacterial Plasmid. Avicenna J Med Biotechnol 2012; 4(1): 15-22.
  29. Helle SI. The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab 2004; 18(1): 67-79.
  30. LÖnning PE, Helle SI. IGF-1 and breast cancer. In: Biology of IGF-1: Its interaction with insulin in health and malignant states. Novartis. Foundation Symposium 262. Chichester, UK: Wiley; 2008.
Journal of Isfahan Medical School
Volume 31, Issue 254 - Serial Number 254
July and August 2013
Pages 1560-1567

Files

History

  • Receive Date: 09 May 2013
  • Revise Date:
  • Accept Date: 06 April 2022

Share

How to cite

Statistics